Abstract:The study of modified RNA known as epitranscriptomics has become increasingly relevant in our understanding of disease-modifying mechanisms. Methylation of N6 adenosine (m6A) and C5 cytosine (m5C) bases occur on mRNAs, tRNA, mt-tRNA, and rRNA species as well as non-coding RNAs. With emerging knowledge of RNA binding proteins that act as writer, reader, and eraser effector proteins, comes a new understanding of physiological processes controlled by these systems. Such processes when spatiotemporally disrupted within cellular nanodomains in highly specialized tissues such as the brain, give rise to different forms of disease. In this review, we discuss accumulating evidence that changes in the m6A and m5C methylation systems contribute to neurocognitive disorders. Early studies first identified mutations within FMR1 to cause intellectual disability Fragile X syndromes several years before FMR1 was identified as an m6A RNA reader protein. Subsequently, familial mutations within the m6A writer gene METTL5, m5C writer genes NSUN2, NSUN3, NSUN5, and NSUN6, as well as THOC2 and THOC6 that form a protein complex with the m5C reader protein ALYREF, were recognized to cause intellectual development disorders. Similarly, differences in expression of the m5C writer and reader effector proteins, NSUN6, NSUN7, and ALYREF in brain tissue are indicated in individuals with Alzheimer's disease, individuals with a high neuropathological load or have suffered traumatic brain injury. Likewise, an abundance of m6A reader and anti-reader proteins are reported to change across brain regions in Lewy bodies diseases, Alzheimer's disease, and individuals with high cognitive reserve. m6A-modified RNAs are also reported significantly more abundant in dementia with Lewy bodies brain tissue but significantly reduced in Parkinson's disease tissue, whilst modified RNAs are misplaced within diseased cells, particularly where synapses are located. In parahippocampal brain tissue, m6A modification is enriched in transcripts associated with psychiatric disorders including conditions with clear cognitive deficits. These findings indicate a diverse set of molecular mechanisms are influenced by RNA methylation systems that can cause neuronal and synaptic dysfunction underlying neurocognitive disorders. Targeting these RNA modification systems brings new prospects for neural regenerative therapies.

Pumilio-1 mediated translational control of claudin-5 at the blood-brain barrier

KCNH2-3.1 Mediates Aberrant Complement Activation and Impaired Hippocampal-Medial Prefrontal Circuitry Associated with Working Memory Deficits.

CLOZAPINE-RELATED BRAIN NRN1 EXPRESSION PATTERNS ARE ASSOCIATED WITH METHYLATION AND GENETIC VARIANTS IN SCHIZOPHRENIA

Pumilio differentially binds to mRNA 3' UTR isoforms to regulate localization of synaptic proteins

Regulation of synapse density by Pumilio RNA-binding proteins

Dendritic localization of the translational repressor Pumilio 2 and its contribution to dendritic stress granules.

Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia

A spatial single-cell atlas of the claustro-insular region uncovers key regulators of neuronal identity and excitability

Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model

Genetic and Epigenetic Regulation in Lingo-1: Effects on Cognitive Function and White Matter Microstructure in a Case-Control Study for Schizophrenia

Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders

Long-read sequencing reveals the RNA isoform repertoire of neuropsychiatric risk genes in human brain

Effects of microRNA-181b-5p on cognitive deficits in first-episode patients with schizophrenia: Mediated by BCL-2

Cis-effects on gene expression in the human prenatal brain associated with genetic risk for neuropsychiatric disorders

Transcription factor POU3F2 regulates TRIM8 expression contributing to cellular functions implicated in schizophrenia

Human forebrain organoid-based multi-omics analyses of PCCB as a schizophrenia associated gene linked to GABAergic pathways

A Primate-Specific, Brain Isoform of KCNH2 Affects Cortical Physiology, Cognition, Neuronal Repolarization and Risk of Schizophrenia

Increased Dysbindin-1B Isoform Expression in Schizophrenia and Its Propensity in Aggresome Formation

KCTD10 P.c124w Variant Contributes to Schizophrenia by Attenuating LLPS-mediated Synapse Formation.

Single molecule in situ hybridization reveals distinct localizations of schizophrenia risk-related transcripts SNX19 and AS3MT in human brain

Alzheimer's disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication